Corporation, a leader in high definition diagnostics, delivering
ultrasensitive single molecule measurement for the benefit of human
health, today announced the appointment of Kevin Hrusovsky as Executive
Chairman of its Board of Directors.
Hrusovsky brings more than twenty years of experience in life science
and diagnostics industries. Prior to Quanterix, he was President of
PerkinElmer Life Sciences & Technology; CEO of Caliper Life Sciences
(sold to PerkinElmer for $650M); and CEO of Zymark Corporation (sold to
Caliper for $150M). Earlier Hrusovsky was President of FMC Corporation's
Pharmaceuticals and International Agricultural Products and prior to
that held numerous management positions at DuPont. He currently serves
on the board of directors of SynapDx, 908 Devices and Solect Energy.
Hrusovsky received his B.S. in Mechanical Engineering from Ohio State
University and M.B.A. from Ohio Universit. He was awarded the 2013
Entrepreneur of the Year from Ohio State University and holds an
Honorary Doctorate degree from Framingham State University for
contributions to life sciences and personalized medicine.
"I am very much compelled by the potential of Quanterix' Simoa
technology, the caliber of its board and leadership team and by
the important opportunity to positively impact the world," said
The appointment comes as Martin Madaus, formerly the Executive Chairman
of the Board at Quanterix, is appointed Chairman and CEO of
Ortho-Clinical Diagnostics (OCD) following the close of its acquisition
from Johnson & Johnson by the Carlyle Group. Madaus will remain a member
of Quanterix' Board of Directors. "I couldn't be more pleased that Kevin
has accepted to become our new Executive Chairman at Quanterix," said
Madaus. "He is an outstanding leader with a strong track record for
guiding innovative companies, creating value for shareholders and a
great fit for Quanterix. Since the launch of the first Simoa products
last year, the company has experienced rapid growth. Kevin's leadership
and experience will ensure the team at Quanterix has the support needed
to continue that trajectory," said Madaus.
To learn more about Simoa, please visit: www.quanterix.com.
Quanterix is a developer of ground-breaking tools in high definition
diagnostics. Its Simoa platform uses single molecule measurements to
access previously undetectable proteins. With this unprecedented
sensitivity and full automation, Simoa offers significant benefits to
both research and clinical testing applications. Quanterix was
established in 2007 and is located in Lexington, Massachusetts. To learn
more about Quanterix and Simoa, please visit: www.quanterix.com.
[ Back To NFVZone's Homepage ]